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Effect of Recombinant Plasmid pEGFP-AFP-hTNF on
Liver Cancer Cells (HepG2 Cells) in vitro when
Delivered by PEG-PEI/Fe3O4 Nanomagnetic Fluid
Baoxiong Zhuang,1 Yangde Zhang,1 Jian Peng,1 Haowei Zhang,2 Tiehui Hu,1 Jie Zeng,1 Yifan Li1*
Background/Purpose: Gene delivery into liver cancer cells has been a problem. This study aimed to under-
stand the effect of using PEGI/Fe3O4 nanomagnetic fluid as a gene vector for liver cancer gene therapy. An
AFP enhancer aids in the expression of tumor-specific foreign genes in AFP-producing cancer cells like
HepG2 cells, and was utilized in the delivery method in this study.
Methods: We constructed recombinant plasmid PEGFP-AFP-hTNFα, which was transfected into AFP 
positive HepG2 cells and AFP negative Hela cells by PEG-PEI/Fe3O4 nanomagnetic fluid. Fluorescence 
microscopy was used to evaluate the transfection rate of the hTNFα gene in the HepG2 cells 12 hours after
transfection. Reverse transcription polymerase chain reaction (RT-PCR) and western blot were used to 
detect expression of hTNFα gene in the HepG2 cells 48 hours after transfection. Methyl thiazolyl tetra-
zolium (MTT) assay was used to evaluate the inhibitory effect of hTNFα on the proliferation of HepG2
cells. Flow cytometry was used to analyze the apoptosis of HepG2 cells.
Results: Plasmid PEGFP-AFP-hTNFα delivered by PEG-PEI/Fe3O4 nanomagnetic fluid was successfully
transfected into HepG2 cells and expressed in the HepG2 cells. The transfection efficacy of hTNFα gene
delivered by PEG-PEI/Fe3O4 nanomagnetic fluid was superior to that of hTNFα gene delivered by lipofec-
tamine in HepG2 cells. RT-PCR and western blot demonstrated that hTNFα gene was expressed in HepG2
cells that were transfected with complexes of nanomagnetic fluid/PEGFP-AFP-hTNFα. MTT and flow cytom-
etry showed that the hTNFα gene markedly exerted a cell killing effect.
Conclusion: PEG-PEI/Fe3O4 nanomagnetic fluid successfully transfected PEGFP-AFP-hTNFα into HepG2
cells and induced expression of hTNFα gene in the HepG2 cells, thus showing promise as a gene vector for
liver cancer gene therapy. Furthermore, an AFP enhancer can specifically increase the expression of target
genes in cells positive for AFP.
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Primary liver cancer, one of the most common
malignant tumors, leads to nearly 1 million deaths
per year and remains a prominent target for ther-
apy.1−4 Surgical resection may be the mainstay of
treatment for primary liver cancer and offers the
chance of cure, but the 5-year survival rate from
liver cancer has remained fairly static over the
past decade, as chemotherapy is lacking in sensi-
tivity and specificity.5−7 Therefore, new measures
are urgently needed for the treatment of this 
disease. Gene therapy represents a rational new
approach to cancer therapy, which could provide
an adjunct to conventional treatment and has re-
cently become a new focus for researchers and
clinicians within this field.8−10 Tumor cells grow-
ing quickly in cancer stimulate the production 
of blood vessels, and these newly formed tumor
vessels are usually abnormal in form and archi-
tecture. Furthermore, tumor tissue usually lacks
effective lymphatic drainage. Nanovector, carrying
encapsulated drugs, extravasate into the tumor
interstitial space and passively target the tumor
tissue. Once the drug is locally released the local
concentration becomes many times larger than
after conventional systemic intravenous admin-
istration. This type of passive targeting is known
as “enhanced permeation and retention” (EPR)
and the altered lymphatic drainage of the tumor
contributes to this effect. Experiments suggest that
extravasation into tumors can take place if their
diameter is < 400 nm, and becomes more effec-
tive for sizes < 200 nm.11 Gene therapy for liver
cancer will allow the use of a target cell-specific
expression system, enabling therapy selectively
aimed at genes expressed in liver cancer cells, which
will reduce damage to normal liver cells.12−15
Gene therapy for liver cancer requires a vector
that can safely and efficiently transfect target
genes into the targeted organ.14 Therefore, we
constructed a recombinant plasmid, PEGFP-AFP-
hTNFα, containing reporter gene green fluores-
cent protein and the hTNFα target gene under
the control of an AFP enhancer. PEG-PEI/Fe3O4
nanomagnetic fluid was used as a gene transfer
vector,16 recombinant plasmid PEGFP-AFP-hTNFα
was electively transfected into AFP-positive hepa-
tocellular carcinoma cells HepG2 in vitro.
PEG-PEI/Fe3O4 nanomagnetic fluid, a gene
transfer vector, is a fluid containing ultra-fine
magnetic iron particles, which has both the mag-
netic characteristic of solid iron and the fluidity
of a liquid. The fluidity of PEG-PEI/Fe3O4 can be
oriented and positioned by exposing it to mag-
netic fields, and has been applied in many areas,
such as using target drug vectors, X-ray radiopaque
contrast agents, and embolization agents.17−20 By
exposing tissue to alternative magnetic fields 
in vivo, nanomagnetic fluid can absorb electromag-
netic energy and transform it into heat energy,
which can increase the temperature of surround-
ing tissues, enabling its application as heat ther-
apy in cancer treatment. Some studies have shown
that PEG-PEI/Fe3O4 nanomagnetic fluid, as a vec-
tor for chemotherapy, is phagocytized by cancer
cells in vitro, and produces heat energy by absorb-
ing electromagnetic wave energy in alternative
magnetic fields in vivo. This characteristic was then
used to kill cancer cells.21,22 Magnetic particles are
evacuated from the body via the normal meta-
bolic pathways involved in cancer cell apoptosis.
Materials and Methods
Materials
PEG-PEI/Fe3O4 nanomagnetic fluid was prepared
by our laboratory. DH5α coli were preserved by
our center. pEGFP-N1 vector was purchased from
Promega (Madison, WI, USA). Plasmid pMD18-
T-hTNFα was a gift from the Cancer Research
Institute of Central South University (Hunan,
China). Restriction enzyme and ligase were pur-
chased from Takara Biology Incorporation (Shiga,
Japan). Lipofectamine™ 2000 was purchased from
Qiagen Incorporated (Valencia, CA, USA). Hepa-
tocellular carcinoma cells (HepG2) and cervical
cancer cells (Hela) were provided by the China
Center for Type Culture Collection of Wuhan
University (Wuhan, China), and preserved by our
center. The Methylthiazolyldiphenyl-tetrazolium
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bromide (MTT) Kit, fetal bovine serum (FBS),
RPMI1640 medium, and TdT fluid were pur-
chased from Sigma (St. Louis, MO, USA). The
PCR and Trizol Kits were purchased from Gibco
(Carlsbad, CA, USA). All other chemical reagents
were obtained commercially as reagent-grade
products.
Methods
Amplification and cloning of hTNFa and 
the AFP enhancer
Primers were designed for polymerase chain re-
action (PCR) amplification following the extrac-
tion of DNA from liver cancer tissues in patients
with high expression of AFP, in accordance with
locus of enhancer core sequences in AFP genes.5
The length of amplified fragment was approxi-
mately 461 bp, and PCR products were separated
and purified using gel electrophoresis and a 1.5%
agarose gel. Following separation and purifica-
tion, the PCR products were inserted into the
PGEM-7Zf (+) vector to construct the plasmid
pGEM-7Zf-AFP after sequencing. According to
the gene sequence of hTNFα (NM: 000594) in
GenBank, the pMD18-T-hTNFα plasmid was used
as a template for PCR amplification. PCR ampli-
fication was performed and yielded products 702
bp in length. The PCR products were separated
and purified on a 1.5% agarose gel (as above).
Following separation and purification, PCR prod-
ucts were inserted into the PEGFP-N1 vector to
construct the pEGFP-hTNFα plasmid.
Construction of recombinant plasmid PEGFP-
AFP-hTNFa
pGEM-7Zf-AFP and pEGFP-hTNFα were digested
with restriction enzyme HindIII and Xhol, and
were then ligated using a ligation reaction sys-
tem. The ligation reaction system was composed
of T4 DNA ligase (1 μL), buffer (1 μL), double
distilled water (4 μL), GEM-7Zf-AFP fragment
(3 μL) and pEGFP-hTNFα fragment (1 μL), and
was stored overnight at 16°C. The final recombi-
nant plasmid PEGFP-AFP-hTNFα was constructed
through ligation, transformation, amplification
and identification.
Transfection of hTNFa in HepG2 and Hela cells
mediated by PEG-PEI/Fe3O4 nanomagnetic fluid
HepG2 cells and Hela cells, in the logarithmic
phase, were seeded into 24-well plates until 70%
confluence was reached. At this time cells were
transfected with plasmid PEGFP-AFP-hTNFα/
nanomagnetic fluid complexes. The same trans-
fection study was repeated at least three times.
Fluorescence microscopy was used to evaluate the
rate of gene transfection in HepG2 cells 12 hours
after transfection.
Reverse transcription polymerase chain reaction 
(RT-PCR) for target gene, hTNFa, expression in the
HepG2 cells
HepG2 cells were plated into 96-well tissue culture
plates, which were divided into three experimental
groups. The groups were the nanomagnetic fluid
gene transfer group (ratio of plasmid DNA/nano-
magnetic fluid complexes was 1:10), the liposome
gene transfer group (ratio of plasmid DNA/lipo-
some complexes was 1:10) and the plasmid control
group (only plasmid pEGFP-AFP-hTNFα, without
transfection vector). Total RNA extracted using a
Trizol Kit was combined with hTNFα primers for
PCR amplification 48 hours after transfection.
The PCR products were separated and purified
on the 1.5% agarose gel using electrophoresis.
Analysis of hTNFa gene expression in transfected
HepG2 cells by western blot
As mentioned above, HepG2 cells were divided
into three experimental groups. Medium was dis-
carded 48 hours after transfection, and cells were
rinsed three times with ice cold PBS buffer. Cells
were then lysed in cell culture lysis buffer and total
cell proteins were separated and purified via dis-
continuous SDS-PAGE gel electrophoresis. After
electroblotting, the membrane was blocked, in
blocking solution (5% non-fat milk), to prevent
unspecific protein binding to antibodies. The
membrane was incubated with primary antibody
(goat anti-human TNFα polyclonal antibody,
1:100 dilution, Santa Cruz) in blocking solution
at 4°C overnight with shaking. The antibody 
solution was then removed and the membrane
Killing effect of pEGFP-AFP-hTNF on HepG2 cells
J Formos Med Assoc | 2011 • Vol 110 • No 5 329
washed three times. Finally, the membrane was in-
cubated with an appropriate secondary antibody
(horse anti-goat IgG/HRP, 1:400 dilution, Santa
Cruz) for 2 hours at room temperature in 5% milk.
Following this incubation period, antibody solu-
tion was removed and the membrane was washed
three times. The membrane was soaked in HRP-
enzyme-linked antibody chromogenic solution,
and was rinsed in distilled water after the target
protein band on the gels were visible. Findings
were compared with tubulin (loading control).
Gene transfection efficiency of the hTNFa gene
mediated by different gene vectors
HepG2 cells were plated into 96-well culture plates,
which were divided into two experimental groups:
the nanomagnetic fluid gene transfer group and
the liposome gene transfer group. Ratio of plasmid
DNA/nanomagnetic fluid complexes was 1:5, 1:10
and 1:20 in the nanomagnetic fluid gene transfer
group, 1:10, 1:20 and 1:40 in the liposome gene
transfer group. Transfection efficiency of HepG2
cells was detected by fluorescence microscope 12
hours, 24 hours and 48 hours after transfection.
Detection of transfection efficiency using 
flow cytometry (FCM)
HepG2 cells were plated into 96-well tissue culture
plates, which were divided into three experimen-
tal groups: the nanomagnetic fluid gene transfer
group, the liposome gene transfer group and the
plasmid control group (pEGFP-AFP-hTNFα, with-
out transfection vector). HepG2 cells were trans-
fected with plasmid DNA/gene vector complexes
to determine the efficiency of each transfection
method. HepG2 cells were transfected with only
the pEGFP-AFP-hTNFα plasmid, without transfec-
tion vector in the plasmid control group. HepG2
cells were detected by flow cytometry after transfec-
tion. The same experiment was repeated five times.
Detection of the inhibitory effects of the recombinant
plasmid PEGFP-AFP-hTNFa on HepG2 cells
mediated by PEG-PEI/Fe3O4 nanomagnetic fluid
HepG2 cells were plated into 96-well culture
plates, which were divided into two experimental
groups: the nanomagnetic fluid gene transfer group
and nanomagnetic fluid control group (only PEG-
PEI/Fe3O4 nanomagnetic fluid, without recombi-
nant plasmid PEGFP-AFP-hTNFα). HepG2 cells
were transfected with plasmid DNA/gene vector
complexes to determine transfection efficiency, but
in the nanomagnetic fluid control group, HepG2
cells were transfected with only PEG-PEI/Fe3O4
nanomagnetic fluid, without recombinant plas-
mid PEGFP-AFP-hTNFα. MTT solution (10μL) was
added into each well of both groups 24 hours,
48 hours, 72 hours and 96 hours after transfection.
The medium was removed after cells were incu-
bated at 37°C for 4 hours, whereupon 200 μL
DMSO was added into each well to dissolve the
formazan. Absorbance was measured on an ELISA
plate reader with a test wavelength of 570 nm. Each
group was designed to 4 Double-Pored, and data
obtained was analyzed with statistical calculations
to compare the survival rate of cells in each group
at different periods.
Detection of HepG2 cell apoptosis using FCM
HepG2 cells were plated into 96-well plates, which
were divided into five experimental groups: the
nanomagnetic fluid gene transfer group, liposome
gene transfer group, nanomagnetic fluid transfer
blank vector group, nanomagnetic fluid control
group and blank control group. HepG2 cells in
all groups were transfected with plasmid DNA/
gene vector complexes to determine transfection
efficiency. Recombinant plasmid PEGFP-AFP-
hTNFα was transfected into HepG2 cells in the
nanomagnetic fluid gene transfer group and li-
posome gene transfer group, and PEGFP-N1 was
transfected into HepG2 cells in the nanomagnetic
fluid transfer blank vector group. PEG-PEI/Fe3O4
nanomagnetic fluid was only added to HepG2
cells in the nanomagnetic fluid control group, 
finally. Nothing was transfected into HepG2 cells
in the blank control group. Forty-eight hours after
transfection, cells were collected with 0.25%
trypsin digestion, and fixed with 70% ethanol for
24 hours. Transfected HepG2 cells in all groups
were then sent to the Beijing Dingguo Bio Corp
for analysis using FCM.
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Statistical analyses
Statistical calculations (Student t test) in each group
were performed using SPSS software version 12.0.
The statistical significance level was set at p < 0.05.
Statistical calculations were performed with sin-
gle faction variance analysis between groups.
Results
Amplification of AFP enhancer by PCR
The length of amplified fragment seen when PCR
products were separated and purified on a 1.5%
agarose gel was approximately 461bp (Figure 1A).
This fragment size is consistent with that of the
target fragment, and the length of the PCR am-
plified fragment was also consistent with that
published on GenBank.23
Preparation and identification of 
PEGFP-AFP-hTNFa
The pGEM-7Zf-AFP plasmid was digested by
Hind II and Xhol to obtain target fragments about
461 bp in length (Figure 1B). This finding sug-
gested that AFP enhancer was successfully inserted
into the pGEM-7Zf (+). The pEGFP-hTNFα plas-
mid was digested by EcoR I and Hind II.I to ob-
tain a target fragment of 702 bp (Figure 1C),
which indicated that the hTNFα gene was suc-
cessfully inserted into the eukaryotic expression
vector, PEGFP-N1.
PEGFP-AFP-hTNFα plasmids were digested
by EcoR I and Hind III to obtain target fragments
with a length of approximately 702 bp. Target
fragments 461 bp long were also obtained when
PEGFP-AFP-hTNFα was digested using Hind II
and Xhol (Figure 1D). These findings indicated
that AFP enhancer and the hTNFα gene were suc-
cessfully inserted into the eukaryotic expression
vector, PEGFP-N1.
Expression of PEGFP-AFP-hTNFa in 
HepG2 and Hela cells
HepG2 cells and Hela cells were observed by flu-
orescent microscopy (Figure 2A). 24 hours after
transfection, the total number of green fluorescent
protein (GFP) positive of Hela cells were less than
that of HepG2 cells. The total amount of GFP in
HepG2 cells increased with hours, and reached 
a peak at 48 hours after transfection, which was
then followed by a decrease in GFP signal. The
total amount of GFP in Hela cells, however, did
not markedly increase over time, which indicated
that the AFP enhancer could potently increase
high-level specific expression of an exogenous
gene in AFP-positive cells.
Comparison of transfection efficiency
between nanomagnetic fluid and liposomes
Transfection efficiency was the highest when the
ratio of plasmid DNA/liposome was 1:40 and
the ratio of plasmid DNA/nanomagnetic fluid
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Figure 1. Preparation and identification of PEGFP-AFP-
hTNFα. (A) PCR analysis of AFP enhancer by gel elec-
trophoresis; a = DL-2000 DNA Marker, b = AFP enhancer.
(B) gel electrophoresis analysis of pGEM-7Zf-AFP products
digested by the Hind II and Xhol; a = Marker, b = positive
clone pGEM-7Zf-AFP. (C) gel electrophoresis analysis of
pEGFP-hTNFα products digested by EcoRI and Hind III
a = Marker, b = positive clone pEGFP-hTNFα. (D) gel elec-
trophoresis analysis of pEGFP-AFP-hTNFα products digested
by EcoR I, Hind III and Hind III, Xhol; a=Marker, b=positive
clone pEGFP-AFP-hTNFα digested by Hind III and Xhol,
c = positive clone pEGFP-AFP-hTNFα digested by EcoR I
and Hind III.
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was 1:10. HepG2 cells, in all groups, were trans-
fected with plasmid DNA/gene vector complexes
with the greatest transfection efficiency, as detected
by FCM (Figure 2B).
Detection of the hTNFa gene in HepG2 cells
using RT-PCR and western blot analysis
The products of the nanomagnetic fluid gene
transfer group and liposome gene transfer group
formed a RNA/cDNA band of 702 bp, which is
consistent with the DL-2000 DNA Marker. How-
ever, the plasmid control group did not display
the protein band at 702 bp (Figure 3A). Western
blot analysis was performed to determine the
molecular weight of the expression products. The
products of the nanomagnetic fluid gene transfer
group and liposome gene transfer group formed
a specific protein band of 45 kDa, consistent
with the molecular weight of tubulin. However,
the plasmid control group did not display the
protein band at 45 kDa (Figure 3B). The results
suggested that PEG-PEI/Fe3O4 nanomagnetic fluid
had successfully transfected recombinant plasmid
PEGFP-AFP-hTNFα into HepG2 cells as a gene
10
1 2 3
35
25
30
20
15
5
0
40
C
el
l t
ra
ns
fe
ct
io
n 
ef
fi
ci
en
cy
 (
%
)
BA
a b
c d
Figure 2. The transfection efficiency of PEGFP-AFP-hTNFα in the cells. (A) fluorescence microscope observation of trans-
fected cells; a = 24 hours after transfection HeLa cellS; b = 24 hours after transfection HepG2 cellS; c = 48h after transfec-
tion HeLa cellS; d = 48h after transfection HepG2 cellS. (B) detection of transfection efficiencies by FCM; 1 = Naked DNA
group; 2 = Lipo/PEGFP-AFP-hTNFα group (p < 0.01, vs naked DNA); 3 = Magnetic fluids/PEGFP-AFP-hTNFα group
(p < 0.01, vs naked DNA and Lipo/DNA).
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Figure 3. The gene expression of PEGFP-AFP-hTNFα in the cells. (A) RT-PCR analysis of HepG2 cells after transfection
with pEGFP-AFP-hTNFα by gel electrophoresis; a = Marker; b = liposome gene transfer group, 702 bp; c = PCR products
of nano-magnetic fluid gene transfer group, 702 bp; d = plasmid control group. (B) detection of hTNFα protein expres-
sion in the HepG2 cells by Westernblot; a = liposome gene transfer group; b = nano-magnetic fluid gene transfer group;
c = plasmid control group.
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vector in vitro, and the hTNFα gene had success-
fully integrated into the HepG2 cells.
The killing effect on HepG2 cells in vitro of
the recombinant plasmid PEGFP-AFP-hTNFa
mediated by PEG-PEI/Fe3O4 nanomagnetic
fluid
MTT assay was performed to determine the sur-
vival rate of the cells. The mean optical density of
the nanomagnetic transfer group was lower than
that of nanomagnetic control group in all periods
following transfection. This difference was statis-
tically significant, as determined by Student t test
(p < 0.05). These results indicated that survival
rate of transfected cells decreased, growth of trans-
fected cells was inhibited, and survival rate of
transfected cells was the lowest (70.9%) 48 hours
after transfection (Figure 4).
Detection of apoptotic cells using FCM
The G1 phase peaks on the left side of recombi-
nant gene transfer group are both peak types of hy-
podiploid cells, showing that the G1 phase of cell
division had been blocked in this group (Figure 5).
The percentage of cells in the S/G2 phase de-
creased, suggesting that cells had undergone apo-
ptosis. Apoptosis rate in the nanomagnetic fluid
gene transfer group was the highest among all
groups at 26.9%, but the lowest in the blank con-
trol group at 3.9%. Apoptosis rate in the nano-
magnetic fluid gene group and nanomagnetic fluid
transfer blank vector were close to that of the blank
control group, indicating that apoptosis of cells
was induced by the target hTNFα gene (Figure 5).
Discussion
Human tumor necrosis factor alpha (TNFα), a
pro-inflammatory cytokine, is synthesized and
secreted by several types of cells, but especially
by macrophages. It has been reported that TNFα
has a strong anti-tumor effect, markedly inhibiting
tumor growth by inducing tumor cell necrosis.24
However, the clinical use of TNFα is severely limited
by its high toxicity and unwanted side effects, such
as severe hypotension, hyperpyrexia and organ
failure. Higher doses of TNFα may not only ex-
hibit higher cytotoxicity, but also lead to systemic
toxicity, while the narrow therapeutic index of
TNFα may limit its utility as an anticancer
agent.25,26 A promising response to this problem
is to transfect the TNFα gene into tumor cells in
the hope of increasing its antitumor effects and
decreasing unwanted side effects.27,28
In this study, we successfully constructed the
recombinant plasmid PEGFP-AFP-hTNFα (Figure
1C and Figure 2A), and the use of PEG-PEI/Fe3O4
nanomagnetic fluid specifically transfected the
target hTNFα gene into AFP-positive HepG2 cells.
PEG-PEI/Fe3O4 nanomagnetic fluid with a size
range of 80–100 nm prepared by our group has
many advantages, such as low toxicity, reducing
damage to other organs, tissues and cells, ability
to target orientation, and improving transfection
efficiency.16 Small size and magnetism of nano-
magnetic carriers solves the problem of emboliza-
tion failure and ectopic embolization in the period
of cancer embolization therapy. PEG-modified
nanomagnetic fluid prolonged the time of cir-
culation in vivo, which avoided phagocytosis by
phagocytic cells and enhanced biocompatibility.
The fluid also has bystander effects and a killing
effect on cancer cells. PEG-PEI/Fe3O4 nanomag-
netic fluid prepared by our group in our study,
and a new gene transfer vector, have successfully
transfected recombinant plasmid PEGFP-AFP-
hTNFα into HepG2 cells in vitro. These findings
suggest that the target gene mediated by PEG-
PEI/Fe3O4 nanomagnetic fluid was successfully
transfected and expressed in the HepG2 cells.
Furthermore, transfection efficiency was higher
24
30
40
50
60
70
80
90
100
48 72 96
70.9
78.2
89.4
82.7
Time (hr)
Su
rv
iv
al
 r
at
e 
of
 c
el
ls
 (
%
)
Figure 4. Survival rate of HepG2 cell in all periods after
transfection with pEGFP-AFP-hTNFα.
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than that of liposome as a gene vector (Figure
2A, Figure 2B). Therefore, PEG-PEI/Fe3O4 nano-
magnetic fluid provided a perfect and new non-
viral vector for gene therapy of liver cancer.
In the period of gene therapy for liver cancer,
the use of target cell-specific expression systems
will enable therapeutic gene selectively to liver can-
cer cells, which reduces damage to normal liver
cells.11−15 Previous studies show that the use of
liver cancer-specific regulatory elements allow for
therapeutic targeting of genes selectively expressed
in liver cancer cells, such as the AFP promoter/
enhancer, the albumin promoter, and insulin-like
growth factor II promoter.29−31 The albumin pro-
moter and insulin-like growth factor II promoter,
however, are less used than the AFP promoter/
enhancer to make target gene selectively expres-
sing liver cancer cells, because of non-specific 
expression of the albumin promoter and insulin-
like growth factor II promoter in the liver cancer
cells. AFP is expressed in high levels in the yolk
sac and liver during embryonic development.32,33
In adults, levels of AFP are almost undetectable,
except in patients who have liver cancer. We cons-
tructed a recombinant plasmid PEGFP-AFP-hTNFα
containing reporter gene green fluorescent protein
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Figure 5. Detection of HepG2 cells apoptosis by flow cytom-
etry. (A) nano-magnetic fluid gene transfer group; (B) lipo-
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B. Zhuang, et al
334 J Formos Med Assoc | 2011 • Vol 110 • No 5
and target hTNFα gene under the control of AFP
enhancer in this experiment, and used PEG-
PEI/Fe3O4 nanomagnetic fluid as a gene transfer
vector. PEGFP-AFP-hTNFα was transfected into
AFP-positive hepatocellular carcinoma cells HepG2
and AFP-negative cervical cancer cells Hela in vitro.
Fluorescence microscopy found PEGFP-AFP-
hTNFα was highly expressed in the AFP-positive
hepatocellular carcinoma cells HepG2 after trans-
fection, but less expressed in the AFP-negative cer-
vical cancer cells Hela (Figure 2A). FCM suggested
that PEGFP-AFP-hTNFα markedly inhibited AFP-
positive HepG2 cell growth, but not AFP-negative
cell growth (Figure 4). These results indicated that
the AFP enhancer can specifically enhance the ex-
pression of target gene in cells positive for AFP.
The hTNFα gene was therefore selectively expressed
in liver cancer cells positive for AFP, and markedly
inhibited AFP-positive HepG2 cell growth, but
reduced damage to normal liver cells.
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